<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823052</url>
  </required_header>
  <id_info>
    <org_study_id>HLX002-0201</org_study_id>
    <nct_id>NCT04823052</nct_id>
  </id_info>
  <brief_title>Investigation of Sulindac in Male Fragile X Syndrome Patients Aged 13-40</brief_title>
  <official_title>A Phase IIa, Double-blind, Placebo-controlled Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HX02_01) Alone and Subsequently in Combination With Other Drugs in Adolescent and Adult Males With Fragile X Syndrome (FXS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healx Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healx Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the safety, tolerability and efficacy of Sulindac in males with&#xD;
      Fragile X Syndrome (FXS) with confirmed full FMR1 mutation treated over a 10 week period in&#xD;
      an outpatient setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly assigned to 1 of 3 treatment arms. All treatment arms will be conducted in parallel. Twelve subjects will be included in each arm. The study treatment will be blinded to patients, carers and physicians.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NIH Cognitive Toolbox</measure>
    <time_frame>Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression - I</measure>
    <time_frame>Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aberrant Behavior Checklist</measure>
    <time_frame>Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety, Depression, and Mood Scale</measure>
    <time_frame>Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FXS Domain Specific Concerns</measure>
    <time_frame>Day 70</time_frame>
    <description>The Clinician/Caregiver FXS Domain Specific Concerns allows for the subject specific symptoms of concern to be assessed on an ongoing basis throughout the study. The specific concerns that correlate to the 6 domains (Clinician) or 3 Domains (Caregiver) will be assessed using a 7-point Likert scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of each sulindac dose</measure>
    <time_frame>Day 70</time_frame>
    <description>Incidence of adverse events (AEs) and serious adverse events (SAEs) reported during the study. Change from baseline to Day 70 in physical examinations and assessment of vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kiddie Test of Attentional Performance (KiTAP)</measure>
    <time_frame>Day 70</time_frame>
    <description>Comparison of change from baseline to Day 70 between sulindac dose levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Faces Tobii Eye Tracking</measure>
    <time_frame>Day 70</time_frame>
    <description>Comparison of change from baseline to Day 70 between sulindac dose levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG</measure>
    <time_frame>Day 70</time_frame>
    <description>Comparison of change from baseline to Day 70 between sulindac dose levels in changing resting state whole brain EEG spectra activity in 3 EEG assessments (EEG spectra, auditory evoked response potential (ERP) and Chirp modulated sweep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>Day 70</time_frame>
    <description>Comparison of change from baseline to Day 70 between sulindac dose levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulindac, dose strength 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulindac, dose strength 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac, dose strength 1</intervention_name>
    <description>Sulindac Capsule</description>
    <arm_group_label>Sulindac, dose strength 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac, dose strength 2</intervention_name>
    <description>Sulindac Capsule</description>
    <arm_group_label>Sulindac, dose strength 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject and caregiver are both able to understand English clearly and caregiver can&#xD;
             read and write English to complete study assessments&#xD;
&#xD;
          -  Males aged 13-40 years (inclusive)&#xD;
&#xD;
          -  Has FXS with molecular genetic confirmation of the full FMR1 mutation (&gt;200 CGG&#xD;
             repeats).&#xD;
&#xD;
          -  Weight ≥45 kg&#xD;
&#xD;
          -  Is in general good health as deemed by the Investigator, determined by physical&#xD;
             examination, medical history, and laboratory tests&#xD;
&#xD;
          -  If receiving sertraline, is on a stable, well-tolerated dose for the previous 3 months&#xD;
             with no further changes anticipated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or history of peptic or gastric ulcer or hemorrhage&#xD;
&#xD;
          -  Any chronic major medical comorbid condition deemed by the Investigator as presenting&#xD;
             added risk to the subject, including but not limited to refractory hypertension,&#xD;
             kidney disease, or liver disease&#xD;
&#xD;
          -  Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication&#xD;
&#xD;
          -  Unstable seizure disorder defined by any seizure within 6 months prior to baseline&#xD;
             visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study&#xD;
             entry&#xD;
&#xD;
          -  Individual or family history of myocardial infarction, TIA, peripheral arterial&#xD;
             disease, stroke or other significant cardiovascular disease&#xD;
&#xD;
          -  Chronic use of NSAIDs or other anti-inflammatory agents&#xD;
&#xD;
          -  Currently taking or have taken any cannabidiol (CBD) preparation within 30 days prior&#xD;
             to randomization&#xD;
&#xD;
          -  Currently taking or have taken sulindac within 30 days prior to randomization&#xD;
&#xD;
          -  Changes in chronic psychotropic or anti-convulsant (where taken for reasons other than&#xD;
             seizure control) drug treatment within 30 days prior to randomization&#xD;
&#xD;
          -  History of adverse effects of sulindac or other NSAIDS that would prevent safe study&#xD;
             completion&#xD;
&#xD;
          -  Unable or unwilling to take oral medication (whole capsule) or history of dysphagia or&#xD;
             malabsorption&#xD;
&#xD;
          -  Has current or suspected symptoms of COVID-19 including, but not limited to fever, dry&#xD;
             cough, new loss or change of smell or taste, myalgia, fatigue, or a positive COVID-19&#xD;
             test.&#xD;
&#xD;
          -  Has abnormal baseline laboratory assessments including, but not limited to alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.5 × the upper limit of&#xD;
             normal (ULN), total bilirubin or creatinine &gt;1.0 × ULN, or other clinically relevant&#xD;
             laboratory abnormality&#xD;
&#xD;
          -  Has a clinically significant abnormal electrocardiogram (ECG), heart rate, or blood&#xD;
             pressure at screening as judged by the Investigator&#xD;
&#xD;
          -  Has received an investigational drug (either approved or not approved) in any prior&#xD;
             clinical study within 30 days or 5 half-lives (whichever is longer) prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Berry-Kravis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kayla Rojas</last_name>
      <phone>720-777-2137</phone>
      <email>kayla.rojas@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Nicole Tartaglia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Luan McColl</last_name>
      <phone>404-778-8619</phone>
      <email>jean.luan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Talboy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Centre</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathryn Kudlacz</last_name>
      <phone>312-563-9473</phone>
      <email>kathryn_L_kudlacz@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Berry-Kravis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bonnie Lerman</last_name>
      <phone>212-241-2995</phone>
      <email>bonnie.lerman@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Alex Kolevzon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>FXS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

